The CELF5 antibody targets the CELF5 protein, a member of the CUGBP Elav-like family (CELF) of RNA-binding proteins. CELF proteins regulate RNA metabolism, including splicing, stability, translation, and localization. CELF5. encoded by the *CELF5* gene in humans (chromosome 15q25.3), contains conserved RNA recognition motifs (RRMs) critical for binding mRNA and modulating post-transcriptional processes. It is highly expressed in the brain, muscle, and testes, suggesting roles in neuronal function, neuromuscular signaling, and spermatogenesis.
Research highlights CELF5's involvement in neurodevelopment and disease. It regulates alternative splicing of synaptic proteins and ion channels, impacting neuronal excitability and synaptic plasticity. Dysregulation of CELF5 has been linked to neurological disorders, including autism spectrum disorder (ASD), intellectual disability, and amyotrophic lateral sclerosis (ALS). In ALS, aberrant CELF5 activity may disrupt RNA processing in motor neurons, contributing to neurodegeneration. Additionally, CELF5 is implicated in cancer, where altered expression correlates with tumor progression and metastasis in certain malignancies.
CELF5 antibodies are essential tools for detecting protein expression, localization, and interactions in experimental models (e.g., Western blot, immunohistochemistry). They enable studies on CELF5's role in RNA-binding dynamics, disease mechanisms, and potential therapeutic targets. However, antibody specificity and validation remain critical due to homology among CELF family members. Understanding CELF5's molecular functions and pathological relevance continues to advance insights into RNA-mediated diseases and precision medicine approaches.